2370 Stock Overview
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MEDINET Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥46.00 |
| 52 Week High | JP¥72.00 |
| 52 Week Low | JP¥41.00 |
| Beta | 0 |
| 1 Month Change | -9.80% |
| 3 Month Change | 2.22% |
| 1 Year Change | -32.35% |
| 3 Year Change | -20.69% |
| 5 Year Change | -36.99% |
| Change since IPO | -93.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2370 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -1.0% |
| 1Y | -32.4% | -37.1% | 27.9% |
Return vs Industry: 2370 exceeded the JP Life Sciences industry which returned -37.1% over the past year.
Return vs Market: 2370 underperformed the JP Market which returned 27.9% over the past year.
Price Volatility
| 2370 volatility | |
|---|---|
| 2370 Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 2370 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2370's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Kanenao Kubushiro | www.medinet-inc.co.jp |
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products.
MEDINET Co., Ltd. Fundamentals Summary
| 2370 fundamental statistics | |
|---|---|
| Market cap | JP¥11.76b |
| Earnings (TTM) | -JP¥3.05b |
| Revenue (TTM) | JP¥998.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 2370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2370 income statement (TTM) | |
|---|---|
| Revenue | JP¥998.00m |
| Cost of Revenue | JP¥668.00m |
| Gross Profit | JP¥330.00m |
| Other Expenses | JP¥3.38b |
| Earnings | -JP¥3.05b |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 2370 perform over the long term?
See historical performance and comparison